Navigation Links
Filing Yaz Class Action Lawsuits Before They Expire
Date:7/18/2012

HOUSTON, July 18, 2012 /PRNewswire/ -- The attorneys at Pulaski & Middleman, LLC are actively representing women affected by the adverse side effects of the birth control drugs Yaz and Yasmin and the maker of the drugs, Bayer Pharmaceuticals. Medical malpractice lawyers are committed to protecting the legal rights of women who have been misinformed of the risks of taking these drugs.  The cutoff date for filing has not yet been determined, but the current Class Action Settlement will likely close within a year or less. Since the timeframe is unclear, it is highly recommended that women take action and file their suits now.

Bayer Pharmaceuticals recently indicated which types of cases it would agree to settle as well as what the average amount would be. More than 10,000 individuals have filed a Yaz lawsuit. The formal class action lawsuit is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation.

The most common lawsuits that have been filed are by women have suffered stroke, Deep Vein Thrombosis (DVP) or Pulmonary Embolism after taking Yaz. Recent studies have linked drospirenone, the chemical present in the birth control drugs, to blood clots that can cause these conditions to occur. The FDA recently released a study, which followed more than 825,000 women taking oral contraceptives and found that women taking Yaz face up to a 74% increased risk of developing blood clots, DVT and pulmonary embolism.

The law office of Pulaski & Middleman, LLC urges women who have experienced these life-threatening injuries to contact an experienced personal injury lawyer and investigate your rights now. The window of time to claim your injury is small as it took Bayer Pharmaceuticals 4 years to open up the settlements.

Contact the experienced Yaz attorneys at Pulaski & Middleman, LLC today if you or a loved one has experienced the harmful effects of the birth control drug. Contact toll
'/>"/>

SOURCE Pulaski & Middleman, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
2. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
3. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
4. Attorneys for Class of Female VPs and SVPs Employed by PR Giant MSLGroup Clarify Companys Inaccurate Description of Federal Courts Recent Certification Ruling
5. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
6. Sanford Wittels & Heisler Files $100 Million Gender Discrimination Class Action In Southern District Of New York
7. Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device
8. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
9. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
10. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
11. eCardios CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 / -- China Nepstar Chain Drugstore Ltd. (NYSE: ... leading retail drugstore chain in China ... today announced the appointment of Ms. Rebecca Yingnan ... immediately. Ms.Zhang has over 20 years ... in March 1999. Prior to Ms. Zhang,s appointment as ...
(Date:11/24/2014)... Juno Therapeutics today announced that the ... company,s JCAR015 chimeric antigen receptor product candidate.  The ... refractory B-cell acute lymphoblastic leukemia and was filed ... Center, where Phase 1 clinical trials are currently ... important news for patients who may benefit from ...
(Date:11/24/2014)... YORK , Nov. 24, 2014  Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... to present at the LD MICRO "MAIN Event" Micro-Cap ... will be held at the Luxe Sunset Bel Air ... Los Angeles, California . ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Relmada Therapeutics To Present At LD MICRO Conference 2
... NEW YORK, Dec. 6, 2010 Keryx Biopharmaceuticals, ... data presented for the first time at the ... Hematology showing promising clinical activity, safety and tolerability ... leukemia (CLL) and Hodgkin,s lymphoma (HL).  KRX-0401 (perifosine) ...
... L.P. unveiled an enhanced version of its popular educational ... easier for healthcare professionals, people with pain and their ... tools. For more than 17 years, the Partners Against ... the quality of pain management for individuals touched by ...
Cached Medicine Technology:Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 2Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 3Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 4Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 5Purdue Pharma L.P. Re-launches Partners Against Pain Website 2
(Date:11/26/2014)... (PRWEB) November 26, 2014 Louisiana ... relief and specialists in minimally invasive spine surgery, ... Shamieh into the rapidly growing provider network of ... The addition coincides with the network’s continuing success ... treatment for Louisiana residents who are suffering from ...
(Date:11/26/2014)... 2014 Sonoran Vein and Endovascular ... the Distinguished Preceptorship Award from The American ... in the advancement of nurse practitioners. The Distinguished ... who had made a significant contribution toward increasing ... Association of Nurse Practitioners (AANP) is the largest ...
(Date:11/26/2014)... Nov. 25, 2014 (HealthDay News) -- Youngsters who enter ... new study suggests. Early puberty was linked with ... poor self-image and high anxiety levels, according to the ... such as conflict with family and peers, and having ... study found. Although the study found an association ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Teens prescribed anti-anxiety ... abuse those drugs than other teens, a new ... to conduct substance abuse assessments on teenagers before ... "Prescribers and parents don,t realize the abuse ... at the University of Michigan School of Nursing. ...
(Date:11/26/2014)... Exposure to peanut protein in household dust may increase ... skin condition eczema, a new study reveals. About ... are allergic to peanuts. And severe eczema in infants ... the researchers noted. The new study included 359 ... examined the amount of peanut protein the children were ...
Breaking Medicine News(10 mins):Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2
... weight loss drugs are really safe, an analysis of previous ... was conducted. What// came to light was the lack of ... ,Two Canadian researchers, Raj Padwal and Sumit Majumdar of ... like sibutramine (Meridia), orlistat (Xenical) and rimonabant (Acomplia) are no ...
... new proposal released by Gov. Arnold Schwarzenegger recently, workers ... double benefit - to their// health and wealth. Employees ... be exempted from tax. ,The proposal is ... is reachable to the approximate 6.5 million Californians who ...
... towards understanding how the human brain learns to recognize ... of Technology, in 2003 launched a project to study ... Prakash" aims to study, identify and, treat, children who ... a lady born blind was studied by the professor, ...
... India plans to promote the development of public-private partnerships ... the National AIDS Control Programme (NACP-III) is likely to ... that approx. 80 per cent of the Indians seek ... per cent for inpatient care. ,A national ...
... diabetes mellitus (NODM) develops in certain patients following a liver ... to develop//, finds that all the risk factors can be ... tailored to the patient's risk ,They found the ... and hepatitis C infection (HCV) paired with the use of ...
... Prevention (CDC) Atlanta's Division of Tuberculosis Elimination feel that ... made TB tests mandatory for all foreign-born nationals, irrespective ... ,Tuberculosis can only be eradicated if all foreign-born ... treated for latent TB infection, they say. ...
Cached Medicine News:Health News:Latest Research on Visual Skills is an Eye Opener 2Health News:Risk Factors That Cause NODM After A Liver Transplant 2Health News:All Foreign-born Nationals In US To Be Tested For TB 2
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large devices for vascular intervention....
Used to introduce balloon, closed and non-tapered end catheters and other devices for intervention....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Medicine Products: